Alcohol, Drug Abuse or Dependence DRG 895 Reimbursement

DRG 895 applies to inpatient cases of alcohol, drug abuse, or dependence that include rehabilitation therapy. This Diagnosis-Related Group is important because it combines acute treatment and rehabilitative services into the payment classification that influences Medicare inpatient reimbursement.

DRG 895 Overview

DRG 895 covers inpatient admissions for patients with alcohol, drug abuse, or dependence who receive rehabilitation therapy during the stay. This Diagnosis-Related Group groups acute medical or psychiatric care combined with active rehabilitation services and drives payment bundling for the hospital episode. It matters for Medicare payment because classification into this group affects relative weight and reimbursement for resource use tied to combined detoxification, medical management, and rehabilitation therapy. Accurate coding of substance use disorders and the delivery of rehabilitative therapy determines eligibility for this Diagnosis-Related Group.

Across commercial payers the observed rate range runs roughly from $370 up to $37K, with individual payer medians and quartiles varying by insurer as shown in the table and chart below. The widest spread is between the lowest minimums (around $370–$450) and the highest maximums ($37K), driven primarily by variation in Cigna and Aetna reported maxima. Refer to the table and chart below for payer-specific median and quartile values.

Alaska Benchmarks

Payer reimbursements for DRG 895 in Alaska range from around $11K (Blue Cross Blue Shield) to $25K (Cigna), with Anthem at a mean of $15K. The state range is relatively compressed compared with national dispersion, and Cigna represents the most notable upward deviation versus other local payers. See the table and chart below for payer-specific percentiles and distribution.

Key Insights for Alaska

Highest-paying payer: Cigna (mean $25K); Lowest-paying payer: BCBS (mean $11K).
Alaska payers span a compact range ($11K–$25K) with Cigna notably above Anthem and BCBS, and BCBS materially below national BCBS median benchmarks where national BCBS median is much lower but national distributions vary.

Studies testing inpatient-delivered behavioral rehabilitation protocols that compare different intensities or modalities of therapy (for example, cognitive-behavioral therapy vs. contingency management or integrated group-plus-individual formats) for patients hospitalized primarily for alcohol or drug dependence. These trials enroll adults admitted for acute detoxification who remain hospitalized for structured rehabilitation services, assessing short-term abstinence, engagement in post-discharge care, and inpatient length of stay. Findings are relevant to providers and payers because they identify which rehabilitative approaches during the index hospitalization most effectively reduce readmissions, shorten costly inpatient episodes, and improve linkage to outpatient services.
Comparative effectiveness trials of models that integrate medical management of withdrawal with co‑occurring psychiatric care and social-services navigation versus standard addiction-only rehabilitation among patients with substance dependence and comorbid mental health or social instability. These studies focus on a higher-complexity subgroup typical in DRG 895—patients with dual diagnoses, homelessness risk, or intensive social needs—and measure outcomes such as stabilization, psychiatric symptom reduction, and utilization of emergency and inpatient services after discharge. Results inform clinical pathways and reimbursement strategies by demonstrating whether integrated inpatient care reduces downstream acute care use and total cost of care for complex patients.
Post-discharge pragmatic trials and longitudinal outcomes research evaluating transitional care interventions (for example, structured discharge planning, rapid outpatient appointment scheduling, and digital monitoring) aimed at improving continuity of addiction treatment and preventing readmission. These studies follow patients discharged from inpatient rehabilitation to assess metrics such as treatment retention at 30–90 days, relapse rates, emergency department visits, and total health care expenditures. This research is important to providers and payers because strong evidence about which transition-of-care strategies lower readmissions and downstream costs can guide resource allocation and reimbursement incentives for hospitals treating this DRG.

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 895. These values summarize Medicare payment and charge levels for the reported discharges in 2023.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$13K	$32K	$12K	3.8K

Patient Population

This DRG’s population is mixed but skewed toward working-age and middle-aged adults rather than predominantly Medicare-age beneficiaries. While Medicare covers a portion of discharges, a substantial share is typically covered by private/commercial payers, reflecting a mixed-age payer distribution. The payer mix therefore includes both Medicare and commercially insured patients rather than being confined to Medicare-age only.

Alaska Benchmarks

Key Insights for Alaska

Highest-paying payer: Cigna (mean $25K); Lowest-paying payer: BCBS (mean $11K).
Alaska payers span a compact range ($11K–$25K) with Cigna notably above Anthem and BCBS, and BCBS materially below national BCBS median benchmarks where national BCBS median is much lower but national distributions vary.

Studies testing inpatient-delivered behavioral rehabilitation protocols that compare different intensities or modalities of therapy (for example, cognitive-behavioral therapy vs. contingency management or integrated group-plus-individual formats) for patients hospitalized primarily for alcohol or drug dependence. These trials enroll adults admitted for acute detoxification who remain hospitalized for structured rehabilitation services, assessing short-term abstinence, engagement in post-discharge care, and inpatient length of stay. Findings are relevant to providers and payers because they identify which rehabilitative approaches during the index hospitalization most effectively reduce readmissions, shorten costly inpatient episodes, and improve linkage to outpatient services.
Comparative effectiveness trials of models that integrate medical management of withdrawal with co‑occurring psychiatric care and social-services navigation versus standard addiction-only rehabilitation among patients with substance dependence and comorbid mental health or social instability. These studies focus on a higher-complexity subgroup typical in DRG 895—patients with dual diagnoses, homelessness risk, or intensive social needs—and measure outcomes such as stabilization, psychiatric symptom reduction, and utilization of emergency and inpatient services after discharge. Results inform clinical pathways and reimbursement strategies by demonstrating whether integrated inpatient care reduces downstream acute care use and total cost of care for complex patients.
Post-discharge pragmatic trials and longitudinal outcomes research evaluating transitional care interventions (for example, structured discharge planning, rapid outpatient appointment scheduling, and digital monitoring) aimed at improving continuity of addiction treatment and preventing readmission. These studies follow patients discharged from inpatient rehabilitation to assess metrics such as treatment retention at 30–90 days, relapse rates, emergency department visits, and total health care expenditures. This research is important to providers and payers because strong evidence about which transition-of-care strategies lower readmissions and downstream costs can guide resource allocation and reimbursement incentives for hospitals treating this DRG.

OpenPayer

Summary & Overview

Alcohol, Drug Abuse or Dependence with Rehabilitation Therapy: Inpatient Reimbursement Overview

DRG 895 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes